We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Strategic Partnership Launches Molecular Assay for Breast Cancer

By LabMedica International staff writers
Posted on 22 Dec 2010
Print article
A real-time polymerase chain reaction (RT-PCR) based panel has been optimized for analysis of ribonucleic acid (RNA) in suspected cancerous tissue samples.

The assay is a breast cancer-segregation panel, which measures 96 genes identified in a proprietary meta-analysis of cancer genomic data from more than 5,000 clinical samples. The RNA is extracted from formalin-fixed, paraffin-embedded (FFPE) tissues.

AltheaDx, Inc., (San Diego, CA, USA) will process and analyze samples in its San Diego-based Clinical Laboratory Improvement Amendments/ Good Laboratory Practice (CLIA/GLP) laboratory. The other partner, Compendia Bioscience, (Ann Arbor, MI, USA), will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials. AltheaDx has facilitated the clinical utilization of biomarkers through validation and clinical sample testing under GLP and/or CLIA. The Breast Cancer Segregation Panel is now available to aid clinical diagnosis.

Francois Ferre, PhD, AltheaDx's cofounder and CEO, said, "Compendia Bioscience is the recognized leader in translating cancer genomic data into meaningful information related to patient outcomes in clinical trials. Compendia's powerful bioinformatics platform is providing highly valuable content around which we can develop predictive tests for our other partners." Daniel R. Rhodes, PhD, cofounder and CEO of Compendia Bioscience added, "AltheaDx has been a pioneering developer of PCR-based assays in clinical settings since its inception with very deep technical capabilities in genetic analysis."

The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials. Under the terms of the partnership, the companies plan to develop Segregation Panels for other cancer types. The next assay, the Colorectal Cancer Segregation Panel, will be released in 2011.

Related Links:

AltheaDx
Compendia Bioscience



New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Lab Sample Rotator
H5600 Revolver

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.